Development of DNA vaccines against hemolytic-uremic syndrome in a murine model

Infection and Immunity

Volumn 71, Issue 7, 2003, Pages 3971-3978

  Capozzo, Alejandra V E ^a   Creydt, Virginia Pistone ^b   Dran, Graciela ^a   Fernández, Gabriela ^a   Gómez, Sonia ^a   Bentancor, Leticia V ^a   Rubel, Carolina ^a   Ibarra, Cristina ^b   Isturiz, Martín ^a   Palermo, Marina S ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VEROTOXIN 2;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; HEMOLYTIC UREMIC SYNDROME; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOBLOTTING; MONOLAYER CULTURE; NEWBORN; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; VACCINATION; VERO CELL;

ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI VACCINES; HEMOLYTIC-UREMIC SYNDROME; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; SHIGA-LIKE TOXIN II; TRANSFECTION; VACCINES, DNA;

EID: 0038648802     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.7.3971-3978.2003     Document Type: Article

References (45)

1. Abe, T., and H. Takaku. 2000. Protection against influenza by genetically engineered vaccines. Nippon Rinsho 58: 2313-2320.
2. Acheson, D. W., S. A. De Breucker, M. Jacewicz, L. L. Lincicome, A. Donohue-Rolfe, A. Kane, and G. Keusch. 1995. Expression and purification of Shiga-like toxin IIB subunit. Infect. Immun. 63:301-308.
3. Bielaszewska, M., I. Clarke, M. A. Karmali, and M. Petric. 1997. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect. Immun. 65:2509-2516.
4. Bosworth, B. T., J. E. Samuel, H. W. Moon, A. D. O'Brien, V. M. Gordon, and S. C. Whipp. 1995. Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine. Infect. Immun. 64:55-60.
5. Bot, A., and L. Bona. 2002. Genetic immunization of neonates. Rev. Microbes Infect. 4:511-520.
6. Bourne, N., G. N. Milligan, M. R. Schleiss, D. I. Bernstein, and L. R. Stanberry. 1996. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 14:1230-1234.
7. Boyer, J. D., A. D. Cohen, S. Vogt, K. Schumann, B. Nath, L. Ahn, K. Lacy, M. L. Bagan, T. J. Higgins, Y. Baine, R. B. Ciccarelli, R. S. Ginsberg, R. R. MacGregor, and D. B. Weiner. 2000. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J. Infect. Dis. 181:476-483.
8. Byun, Y., M. Ohmura, K. Fujihashi, S. Yamamoto, J. R. McGhee, S. Udaka, H. Kiyono, Y. Takeda, T. Kohsaka, and Y. Yuki. 2001. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant cholera toxin elicits serum neutralizing antibodies. Vaccine 19:2061-2070.
9. Cao, C., C. Shi, P. Li, and Q. Ma. 1995. A secretion expression system using promoter and signal peptide of cholera subunit gene. Chin. J. Biotechnol. 11:79-86.
10. Chen, S. C., E. F. Fynan, H. L. Robinson, S. Lu, H. B. Greenberg, J. C. Santoro, and J. E. Herrmann. 1997. Protective immunity induced by rotavirus DNA vaccines. Vaccine 15:899-902.
11. Comerota, A. J., R. C. Throm, K. A. Miller, T. Henry, N. Chronos, J. Laird, R. Sequeira, C. K. Kent, M. Bacchetta, C. Goldman, J. P. Salenius, F. A. Schmieder, and R. Pilsudski. 2002. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J. Vasc. Surg. 35:930-936.
12. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122-1128.
13. Corr, M., D. J. Lee, D. A. Carson, and H. Tighe. 1996. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184:1555-1560.
14. Cuisinier, A. M., V. Mallet, A. Meyer, C. Caldora, and A. Aubert. 1997. DNA vaccination using expression vectors carrying FIV structural genes induces strong immune response against feline immunodeficiency virus. Vaccine 15:1086-1094.
15. Davis, H. L., R. Weeratna, T. J. Waldschmidt, L. Tygrett, J. Schorr, A. M. Krieg, and R. Weeratna. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-876.
16. Donohue-Rolfe, A., D. W Acheson, and G. T. Keusch. 1991. Shiga toxin purification, structure and function. Rev. Infect. Dis. 13:s293-s297.
17. Dupuis, M., K. Denis-Mize, C. Woo, C. Goldbeck, M. J. Selby, M. Chen, G. R. Otten, J. B. Ulmer, J. J. Donelly, G. Ott, and D. M. McDonald. 2000. Distribution of DNA vaccines determines their immunogenicity in mice. J. Immunol. 165:2850-2858.
18. Elango, N., J. Vivekananda, R. Strong, and M. S. Katz. 1997. Nuclei isolation from bone cells for nuclear run-on assays. BioTechniques 23:422-424.
19. Fernández, G., C. Rubel, G. Dran, S. Gómez, M. Isturiz, and M. S. Palermo. 2000. Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome. Clin. Immunol. 95:227-234.
20. Flo, J., B. A. Perez, S. Tisminetzky, and F. Baralle. 2000. Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene. Vaccine 18:3242-3253.
21. Fuerst, T. R., E. G. Niles, F. W. Studire, and B. Moss. 1986. Eukariotic transient expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 polymerase. Proc. Natl. Acad. Sci. USA 83:8122-8126.
22. Fynan, E. R., D. Webster, J. Fuller, J. Haynes, J. Santoro, and H. Robinson. 1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90:11478-11482.
23. Gordon, V. M., S. C. Whipp, H. W. Moon, A. D. O'Brien, and J. E. Samuel. 1992. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect. Immun. 60:485-490.
24. Grigera, P. R., M. García Briones, O. Periolo, J. L. La Torre, and R. R. Wagner. 1996. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. J. Virol. 70:8492-8501.
25. Hii, J. H., C. Gyler, T. Morooka, M. A. Karmali, R. Clarke, S. De Grandis, and J. L. Brunton. 1991. Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1. J. Clin. Microbiol. 29:2704-2709.
26. Ishii, K. J., W. R. Weiss, and D. M. Klinman. 1999. Prevention of neonatal tolerance by a plasmid encoding granulocyte-macrophage colony stimulating factor. Vaccine 18:703-710.
27. Jobling, M. G., L. M. Palmer, J. L. Erbe, and R. K. Holmes. 1997. Construction and characterization of versatile cloning vectors for efficient delivery of native foreign proteins to periplasm of E. coli. Plasmid 38:158-173.
28. Karmali, M. A. 1989. Infection by verotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-38.
29. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T7. Nature 227:680-685.
30. Leclerq, S., J. S. Harms, G. M. Rosinha, V. Azevedo, and S. C. Oliveira. 2002. Induction of a Th1-type of immune response but not protective immunity by intramuscular DNA immunization with Brucella abortus GroEL heat-shock gene. J. Med. Microbiol. 51:20-26.
31. Leitner, W. W., H. Ying, and N. P. Restifo. 2000. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18:765-777.
32. Lewis, P. J., van Drunen Little-van den Hurk, and L. A. Babiuk, 1999. Induction of immune responses to bovine herpes virus type 1 gD in passively immune mice after immunization with a DNA-based vaccine. J. Gen. Virol. 80:2829-2837.
33. Lim, Y. S., B. Y. Kang, E. J. Kim, S. H. Kim, S. Y. Hwang, and T. S. Kim. 1998. Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma hybrid construct. Immunol. 94:135-141.
34. MacGregor, R. R., J. D. Boyer, K. E. Ugen, K. E. Lacy, S. J. Gluckman, M. L. Bagarazzi, M. A. Chattergoon, Y. Baine, T. J. Higgins, R. B. Ciccarelli, L. R. Coney, R. S. Ginsberg, and D. B. Weiner. 1998. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178:92-100.
35. Marcato, P., G. Mulvey, R. J. Read, K. Vander Helm, P. N. Nation, and G. D. Armstrong. 2001. Immunoprophylactic potential of cloned Shiga toxin 2B subunit. J. Infect. Dis. 183:435-443.
36. Matise, I., N. A. Cornick, S. L. Booher, J. E. Samuel, B. T. Bosworth, and H. W. Moon. 2001. Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli. J. Infect. Dis. 183:347-350.
37. McEwen, J., M. Leitner, I. Harari, and R. Arnon. 1989. Expression of Shiga toxin epitopes in E. coli immunological characterization. Immunol. Lett. 21:157-164.
38. Mincheff, M., S. Tchakarov, S. Zoubak, D. Loukinov, C. Botev, I. Altankova, G. Georgiev, S. Petrov, and H. T. Meryman. 2000. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: phase I/II clinical trial. Eur. Urol. 38:208-217.
39. National Institutes of Health. 1998. NIH policy manual, chapter 3035. National Institutes of Health, Bethesda, Md.
40. National Institutes of Health. 1985. Guide for the care and use of laboratory animals. NIH publication no. 85-23. National Institutes of Health, Bethesda, Md.
41. Palermo, M. S., C. Rubel, M. F. Alves Rosa, G. Fernández, F. Alberto, G. Fernández Alonso, M. Rivas, and M. A. Isturiz. 1999. Pretreatment of mice with LPS or IL-1β exerts opposite effects on Shiga-toxin-2 lethality. Clin. Exp. Immunol. 119:77-83.
42. Pisetsky, D. S. 1997. Immunostimulatory DNA: a clear and present danger? Nat. Med. 3:829-831.
43. Sedegah, M., W. Weiss, J. B. Sacci, Jr., Y. Charoenvit, R. Hedstrom, K. Gowda, V. F. Majam, J. Tine, S. Kumar, P. Hobart, and S. L. Hoffman. 2000. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J. Immunol. 164:5905-5912.
44. Williams, J. M., N. Lea, J. M. Lord, L. M. Roberts, D. V. Milford, and C. M. Taylor. 1997. Comparison of ribosome-inactivating proteins in the induction of apoptosis. Toxicol. Lett. 91:121-127.
45. Yamagami, S., M. Motoki, T. Kimura, H. Izumi, T. Takeda, Y. Katsuura, and Y. Matsumoto. 2001. Efficacy of post-infection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738-742.